Somatic mutations of calreticulin in myeloproliferative neoplasms

New England Journal of Medicine

Volumn 369, Issue 25, 2013, Pages 2379-2390

  Klampfl, Thorsten ^a   Gisslinger, Heinz ^b   Harutyunyan, Ashot S ^a   Nivarthi, Harini ^a   Rumi, Elisa ^c   Milosevic, Jelena D ^a   Them, Nicole C C ^a   Berg, Tiina ^a   Gisslinger, Bettina ^b   Pietra, Daniela ^c   Chen, Doris ^a   Vladimer, Gregory I ^a   Bagienski, Klaudia ^a   Milanesi, Chiara ^c   Casetti, Ilaria Carola ^c   Sant'Antonio, Emanuela ^c   Ferretti, Virginia ^c   Elena, Chiara ^c   Schischlik, Fiorella ^a   Cleary, Ciara ^a   Six, Melanie ^a   Schalling, Martin ^b   Schon̈egger, Andreas ^a   Bock, Christoph ^a   Malcovati, Luca ^c,d   Pascutto, Cristiana ^c   Superti Furga, Giulio ^a   Cazzola, Mario ^c,d   Kralovics, Robert ^a,b   more..

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CALR GENE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; EXOME; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; JANUS KINASE 2 GENE; MAJOR CLINICAL STUDY; MPL GENE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SEQUENCE ANALYSIS; SOMATIC MUTATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84890372480     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1311347     Document Type: Article

References (32)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer, 2008.
2. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.
5. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
6. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011;117:2813-6.
7. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270.
8. Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013;121:4388-95.
9. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-9.
10. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
11. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-11.
12. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92.
13. Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904-8.
14. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-6.
15. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011;118:5227-34.
16. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011;25:1219-20.
17. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-6.
18. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008;22:1841-8.
19. Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011;118:167-76.
20. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 Lesions in leukemic transformation. N Engl J Med 2011;364:488-90.
21. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-9.
22. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168-71.
23. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993;12:737-51.
24. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54.
25. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009;114:3538-45.
26. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211-9.
27. Coe H, Jung J, Groenendyk J, Prins D, Michalak M. ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J Biol Chem 2010;285:6725-38.
28. Si J, Collins SJ. Activated Ca2+/cal?mod?ulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res 2008;68:3733-42.
29. Yue X, Wang H, Zhao F, et al. Hepatitis B virus-induced calreticulin protein is involved in IFN resistance. J Immunol 2012;189:279-86.
30. Campbell PJ, Griesshammer M, Döhner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098-100.
31. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8.
32. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120:1197-201.